In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database
NCT03479762 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 105
Last updated 2022-11-25
Summary
This study is conducted in Europe. The aim of this study is to investigate the usage of liraglutide for weight management in clinical practice using the CPRD (Clinical Practice Research Datalink) primary care database.
Conditions
Interventions
- DRUG
-
No treatment given
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Clinical Reporting Office (2834) · Novo Nordisk A/S
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-04-20
- Primary Completion
- 2022-09-12
- Completion
- 2022-09-12
Countries
- Denmark
More Related Trials
-
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
NCT01179048 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity
NCT02918279 ·Status: COMPLETED ·Phase: PHASE3
-
Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects
NCT03041792 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of Liraglutide 3.0 on Body Fat Distribution
NCT03038620 ·Status: COMPLETED ·Phase: PHASE4
-
Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity
NCT03523273 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
NCT04881760 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Liraglutide in Chronic Obstructive Pulmonary Disease
NCT03466021 ·Status: COMPLETED ·Phase: PHASE4
-
A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers
NCT00978393 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
NCT01272219 ·Status: COMPLETED ·Phase: PHASE3
-
Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis
NCT01237119 ·Status: COMPLETED ·Phase: PHASE2
-
Metabolism and Excretion of Liraglutide in Healthy Male Volunteers
NCT01517568 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance
NCT00781937 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers
NCT01507337 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes
NCT01511692 ·Status: COMPLETED ·Phase: PHASE1
-
GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight
NCT04779697 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
NCT01557166 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes
NCT00422058 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes
NCT01272232 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
NCT05929079 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes
NCT01507311 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
NCT07232719 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
NCT04575194 ·Status: UNKNOWN ·Phase: PHASE4
-
A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years
NCT01789086 ·Status: COMPLETED ·Phase: PHASE1
-
Liraglutide and Cardio-Metabolic Risk Markers
NCT01715428 ·Status: COMPLETED
-
Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.
NCT01784965 ·Status: COMPLETED ·Phase: PHASE3